Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD-101 Ophthalmic Solution for Treatment of Myopia in Children
2023-509134-19-00Phase 3Completed
- Sponsor
- Sydnexis Inc.
- Start
- Apr 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in myopia comparing SYD-101 ophthalmic solution with Vehicle (control) (2 arms). Primary endpoints: Mean annual progression rate of myopia through Month 24 and Evaluation of adverse events (AEs) and serious adverse events (SAEs). Started Apr 2024; status: completed.
02
Drugs
SYD-101
03
Conditions
myopia
Beyond the preview
Go deeper on 2023-509134-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509134-19-00.